

REMARKS

This application has been amended in a manner that is believed to place it in condition for allowance at the time of the next Official Action.

Claims 27, 32-33, 44-45 and 47-60 are pending in the present application.

Claims 27, 32-33, 44-45 and 47-48 have been amended to address the formal matters raised in the outstanding Official Action. Claims 49-60 have been added. Support for claims 49-60 may be found in original claims 32, 33, 44 and 45. Claim 46 has been cancelled.

In the outstanding Official Action, claims 27, 32-33 and 44-48 were rejected under 35 USC 112, second paragraph, as allegedly being indefinite to particularly point out and distinctly claim the subject matter which applicant regards as the invention. This rejection is respectfully traversed.

In imposing the rejection, claims 27, 44 and 46-48 were rejected for reciting the term "A β -Arc peptide". The Official Action alleged that the term was indefinite because the claims did not refer to specific sequence identification numbers.

However, at this time, the Examiner's attention is respectfully directed to claim 27. Claim 27 recites that the A β -Arc peptide comprises the mutation Glu₂₂-Gly₂₂. Thus, while a specific sequence identification number is not recited, the A β -Arc peptide is characterized by a specific mutation. Indeed,

this mutation is explained in detail on pages 4 and 6 in the present specification. As a result, while the term may be broad, Applicants believe that the term is definite to one of ordinary skill in the art.

The Examiner's attention is also respectfully directed to claim 44. Claim 44 recites that the A β -Arc peptide is selected from the group consisting of A β 39-Arc (Amino Acids 1-39 of SEQ ID NO:1), A β 40-Arc (Amino Acids 1-40 of SEQ ID NO:1), A β 41-Arc (Amino Acids 1-41 of SEQ ID NO:1), A β 42-Arc (SEQ ID NO:1), and combinations thereof. Thus, claim 44 and its dependent claims plainly recite an A β -Arc peptide in terms of a specific sequence identification number. As a result, Applicants believe that the claims are definite to one of ordinary skill in the art.

Claims 45 and 48 were rejected for allegedly being indefinite for reciting the phrase "a protofibril is in combination with a mutation". However, claims 45 and 48 have been amended so this phrase is no longer recited in the claims. As a result, Applicants believe that this rejection has been obviated.

Claims 27 and 44 rejected for citing the phrase "a therapeutic effective antibody". As suggested by the Examiner, claims 27 and 44 have been amended to recite "a therapeutically effective amount of an antibody". Applicants would like to thank the Examiner for her suggestions on how to overcome this

rejection. As a result, Applicants believe this rejection has been obviated.

Claim 27 was rejected for allegedly being a substantial duplicate of claim 46. However, as cited above, claim 46 has been cancelled. Thus, Applicants believe that this rejection has also been obviated.

In view of the present amendment and foregoing remarks, therefore, Applicants believe that the present application is in condition for allowance at the time of the next Official Action. Allowance and passage to issue on that basis is respectfully requested.


Please charge the fee of \$125.00 for the extra five dependent claim added herewith, to Deposit Account No. 25-0120.

Please charge the fee of \$100.00 for the extra independent claim added herewith, to Deposit Account No. 25-0120.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.


Respectfully submitted,

YOUNG & THOMPSON



Philip Dubois, Reg. No. 50,696
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297
Telefax (703) 685-0573 (703) 979-4709

PD/psf



Docket No. 1510-1030
Appln. No. 09/899,815

rejection. As a result, Applicants believe this rejection has been obviated.

Claim 27 was rejected for allegedly being a substantial duplicate of claim 46. However, as cited above, claim 46 has been cancelled. Thus, Applicants believe that this rejection has also been obviated.

In view of the present amendment and foregoing remarks, therefore, Applicants believe that the present application is in condition for allowance at the time of the next Official Action. Allowance and passage to issue on that basis is respectfully requested.


Please charge the fee of \$125.00 for the extra five dependent claim added herewith, to Deposit Account No. 25-0120.

Please charge the fee of \$100.00 for the extra independent claim added herewith, to Deposit Account No. 25-0120.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON


Philip Dubois, Reg. No. 50,696
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297
Telefax (703) 685-0573 (703) 979-4709

PD/psf